INNOCAN PHARMA CORPORATION

Business Segments InnoCan Pharma Corporation

Equities

INNO

CA45783P1027

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 11:17:31 2025-01-23 am EST			5-day change	1st Jan Change
0.1850 ^CAD	+2.78%		+5.71%	-11.90%

Dec. 31	Innocan Pharma Closes Private Placement for $635,444	MT
Dec. 30	InnoCan Pharma Corporation announced that it has received CAD 0.635445 million in funding	CI

Sales 2023 by Business Segment

See more © MarketScreener.com

Sales 2023 by Geography

See more © MarketScreener.com

Historical Breakdown of Revenue by Business Segments

Operating Income: Breakdown by Business Segment

Breakdown by Business Segment (USD)

Fiscal Period: December	2018	2019	2020	2021	2022	2023
Online Specialty Retail
Online Sales		-	-	-	-	13.55M
Operating Income		-	-	-	-	1.42M
Medicinal Chemicals and Botanical Products
Other Operations		-	-	-	-	109K
Operating Income		-	-	-	-	-5.22M
Pharmaceuticals		-	8K	196K	2.56M	-
Total Assets		2.58M	4.33M	12.58M	6.98M	-
Interest Expense		-40K	-	-13K	-2K	-
Income Tax Expense		-	-	-	1K	-
CAPEX		-9K	-	-41K	-26K	-
EBT		-3.34M	-9.95M	-10.09M	-3.89M	-
Gross Profit		-	3K	121K	2.11M	-
D&A		23K	40K	43K	35K	-
Operating Income		-3M	-4.72M	-7.48M	-6.27M	-
Net Income		-3.34M	-9.95M	-10.05M	-3.76M	-

Geographical Revenue Distribution History

Geographical breakdown of sales (USD)

Fiscal Period: December	2018	2019	2020	2021	2022	2023
United States		-	-	34K	2.42M	13.55M
Rest of The World		-	-	41K	59K	109K
United Kingdom		-	-	-	83K	-
Poland		-	-	60K	-	-
France		-	-	61K	-	-
Israel		-	8K	-	-	-
D&A		-	40K	-	-	-
Total Assets		-	4.33M	-	-	-
Gross Profit		-	3K	-	-	-
Net Income		-	-9.95M	-	-	-
EBT		-	-9.95M	-	-	-
Operating Income		-	-4.72M	-	-	-
Interest Expense		-40K	-	-	-	-
D&A		23K	-	-	-	-
Total Assets		2.58M	-	-	-	-
CAPEX		-9K	-	-	-	-
Net Income		-3.34M	-	-	-	-
EBT		-3.34M	-	-	-	-
Operating Income		-3M	-	-	-	-